Regulus Acquires miRNA IP from NYU | GenomeWeb

Regulus Therapeutics said this week that it has obtained the exclusive rights from New York University to intellectual property covering the modulation of two microRNAs, miR-33a and miR-33b, for the treatment of metabolic diseases including atherosclerosis and metabolic syndrome.

"Regulus scientists and our collaborators at NYU have shown that dysregulation of specific microRNAs, including miR-33a and miR-33b, can drive metabolic disease processes linked to dyslipidemia and atherosclerosis,” Regulus President and CEO Kleanthis Xanthopoulos said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."